Catheter Precision, Inc. Amps Up Sales Efforts with Experienced Team to Fuel Growth

Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in cardiac electrophysiology solutions, recently unveiled its ambitious plan to expand its business development team. By incorporating seasoned industry professionals, the company aims to enhance growth and market reach. CEO David Jenkins expressed confidence in this strategic move, drawing parallels to the team's past success, which significantly contributed to reaching over $100 million in sales for a previously acquired entity.

The expansion plan includes the addition of eight sales veterans, alongside technical experts Madison Spence and David Pollmeier from Acutus and Galaxy Medical respectively. Jenkins highlighted the focus on their VIVO and LockeT product lines, both of which boast a 90% gross margin. This initiative is anticipated to propel the company towards cash flow breakeven by year-end.

Robert Locke, the newly appointed Vice President, shared enthusiasm for replicating previous collaborative successes within Catheter Precision. Citing his one-month tenure's achievements, Locke revealed substantial interest from hospitals in the LockeT product, underscoring its significant potential in not only the U.S. but also globally across various medical disciplines.

With notable products like VIVO - a non-invasive 3D imaging system, and LockeT - a suture retention device enhancing hemostasis post-percutaneous venous punctures, Catheter Precision continues to underscore its commitment to advancing cardiac arrhythmia treatment. The company's forward-looking statements reveal optimism towards fortifying sales endeavors and realizing broad market opportunities.